uniQure (NASDAQ:QURE) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of uniQure (NASDAQ:QURE) to a sell rating in a research note released on Wednesday.

Several other research analysts have also recently commented on the stock. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and raised their target price for the stock from $20.00 to $52.00 in a report on Tuesday, December 10th. The Goldman Sachs Group lifted their price objective on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 12th. Guggenheim restated a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. HC Wainwright raised their price objective on uniQure from $25.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Finally, Cantor Fitzgerald boosted their price objective on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.00.

uniQure Trading Up 1.4 %

NASDAQ:QURE opened at $16.13 on Wednesday. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The company has a 50-day moving average of $14.29 and a 200-day moving average of $9.09.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The business had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million. Equities analysts expect that uniQure will post -3.75 earnings per share for the current year.

Insider Buying and Selling at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.74% of the company’s stock.

Hedge Funds Weigh In On uniQure

Institutional investors have recently added to or reduced their stakes in the company. abrdn plc boosted its stake in uniQure by 381.7% in the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after purchasing an additional 1,528,581 shares in the last quarter. Franklin Resources Inc. bought a new stake in shares of uniQure in the third quarter worth about $7,360,000. Point72 Asset Management L.P. increased its stake in uniQure by 336.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock worth $4,816,000 after purchasing an additional 752,889 shares in the last quarter. Privium Fund Management B.V. raised its holdings in uniQure by 16.3% during the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock worth $3,672,000 after buying an additional 104,500 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of uniQure by 1.3% during the third quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock worth $2,509,000 after acquiring an additional 6,362 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.